Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362440 · ClinicalTrials.gov registry record · Phase 2
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00362440: Completed Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00362440 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00362440, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by your fat cells). Our hope is that they will improve sugar and fat metabolism and positively affect the body fat changes you have noticed while taking HAART.
Interventions
- DRUG Placebo
- DRUG Leptin
- DRUG Pioglitazone or metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00362440 record still lists
NCT00362440 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00362440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00362440 about?
NCT00362440 is a clinical study titled "Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome". The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and leptin (a natural hormone produced by your fat cells). Our hope is that...
What is the current status of trial NCT00362440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00362440?
The interventions under investigation include: Placebo (DRUG), Leptin (DRUG), Pioglitazone or metformin (DRUG).
Who is sponsoring clinical trial NCT00362440?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00362440's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia